EyePoint, Inc. (EYPT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.91

From 52W high−79.58%

Volume7.25M

Market cap$331.92M

P/E (TTM)—

P/S (TTM)119.0x

Div yield—

Key dataSep 18, 2026

Open

$3.91

From 52W high

−79.58%

Volume

7.25M

Market cap

$331.92M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

31.6

MomentumView details →

1D Return

−3.51%

YTD Return

−78.22%

SummaryUpdated Jun 1, 2026

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a specialized pharmaceutical company founded in 1987 and headquartered in Watertown, Massachusetts. Originally incorporated as pSivida Corp, the company rebranded to EyePoint Pharmaceuticals in March 2018 to better reflect its focus on ophthalmic treatments. The company has evolved from a diversified pharmaceutical entity into a clinical-stage biopharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for serious eye diseases. EyePoint operates through strategic partnerships across the United States, China, and the United Kingdom, leveraging its proprietary sustained-release drug delivery technology to address unmet medical needs in ophthalmology.

Ask drillr about EyePoint, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

62.3x

P/S (TTM)

119.0x

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

41.77%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−184.27%

ROA (TTM)

−134.38%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−94.63%

EPS YoY

−39.55%

FCF YoY

−39.81%

Revenue CAGR 3Y

−8.83%

EPS CAGR 3Y

−36.64%

EBITDA YoY

−69.91%

MomentumView details →

1D Return

−3.51%

YTD Return

−78.22%

1Y Return

−69.96%

RSI (14)

31.6

vs 50D SMA

−55.71%

vs 200D SMA

−69.79%

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

4.50x

Quick Ratio

4.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.09

EPS Surprise

−7.92%

Beats (12Q)

4/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

−11.87%

Rev Surprise

12.36%

Financials snapshotView financials →

Revenue (TTM)

2.79M

Net Income (TTM)

−306.64M

Op. CF (TTM)

−267.30M

Next earningsNov 4, 2026 →

Latest newsMore news →

EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).4d ago

Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.23d ago

Similar companies

B&K Corporation Limited02396.HK Century Therapeutics, Inc.IPSC Compass Therapeutics, Inc.CMPX Inhibikase Therapeutics, Inc.IKT Lexeo Therapeutics, Inc. Common StockLXEO SAB Biotherapeutics, Inc.SABS Find similar companies →

Latest newsMore news →

EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).4d ago Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.23d ago